Caller Tal, Moore Kathryn J, Lehmann Lorenz H, Wu Sean M, Leor Jonathan
Neufeld and Tamman Cardiovascular Research Institutes, Faculty of Medical and Health Sciences, Tel Aviv University, Israel (T.C., J.L.).
Lev Leviev Cardiovascular and Thoracic Center, Sheba Medical Center, Tel Hashomer, Israel (T.C., J.L.).
Circ Res. 2025 May 23;136(11):1262-1285. doi: 10.1161/CIRCRESAHA.124.325490. Epub 2025 May 22.
Heart failure (HF) often coexists with cancer. Beyond the known cardiotoxicity of some cancer treatments, HF itself has been associated with increased cancer incidence. The 2 conditions share common risk factors, mechanisms, and interactions that can worsen patient outcomes. The bidirectional relationship between HF and cancer presents a complex interplay of factors that are not fully understood. Recent preclinical evidence suggests that HF may promote tumor growth via the release of protumorigenic factors from the injured heart, revealing HF as a potentially protumorigenic condition. Our review discusses the biological crosstalk between HF and cancer, emphasizing the impact of HF on tumor growth, with inflammation, and modulating the immune system as central mechanisms. We further explore the clinical implications of this connection and propose future research directions. Understanding the mechanistic overlap and interactions between HF and cancer could lead to new biomarkers and therapies, addressing the growing prevalence of both conditions and enhancing approaches to diagnosis, prevention, and treatment.
心力衰竭(HF)常与癌症并存。除了某些癌症治疗已知的心脏毒性外,HF本身也与癌症发病率增加有关。这两种疾病具有共同的危险因素、机制和相互作用,可使患者预后恶化。HF与癌症之间的双向关系呈现出一种尚未完全了解的复杂因素相互作用。最近的临床前证据表明,HF可能通过受损心脏释放促肿瘤因子来促进肿瘤生长,揭示HF是一种潜在的促肿瘤状态。我们的综述讨论了HF与癌症之间的生物学相互作用,强调HF对肿瘤生长的影响,其中炎症和调节免疫系统是核心机制。我们进一步探讨了这种联系的临床意义,并提出了未来的研究方向。了解HF与癌症之间的机制重叠和相互作用可能会产生新的生物标志物和治疗方法,解决这两种疾病日益普遍的问题,并加强诊断、预防和治疗方法。